Sanofi: €4bn hinges on data due by October
This article was originally published in Scrip
Executive Summary
Late-stage data on Sanofi pipeline drugs potentially worth more than €4 billion in annual sales are accumulating, and the next six months will be critical. There are five key Phase III read-outs due by the end of the third quarter, meaning that by October the French firm's mid-term growth potential could look a lot clearer.